OrganiGram Aktie

Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential. » Mehr auf seekingalpha.com

Many legal cannabis operators are working to keep pushing the boundaries of the industry. Innovation is key for any growing sector and cannabis is no different. Right now is a pivotal time for the cannabis industry as things are continuously changing. The climate of the sector and the success of companies can have a direct connection to how most marijuana stocks perform, especially during an election year where promises may come along from presidential candidates to better the industry. » Mehr auf marijuanastocks.com

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tra. » Mehr auf businesswire.com